Breaking News

Agilent, Eurofins to Expand SureVector Cloning System

March 11, 2016

To offer custom components and services for next-gen cloning kits

Agilent Technologies, Inc. and Eurofins Genomics have entered a collaboration to offer custom components and an assembled plasmid service for Agilent’s SureVector next-gen cloning kits. Agilent will also offer a set of catalog components for its SureVector cloning kits, enabling the creation of more than 1 million different cloning vectors.

Agilent has provided molecular biology tools since it acquired Stratagene in 2007. Its products address the entire workflow for molecular and synthetic biology, and SureVector expands this portfolio. Eurofins Genomics provides DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services.

Components of the SureVector system are functional DNA modules that can be rapidly combined to assemble into vectors, which biologists can do in less than 30 minutes, according to the company. The newly released kits contain standard parts for mammalian, E. coli and yeast cells, with Eurofins offering the ability to create custom components for any organism.

“SureVector is part of Agilent’s continued commitment to providing revolutionary tools for molecular biology,” said Alessandro Borsatti, head of genomics marketing for Agilent. “The Eurofins collaboration is an exciting step forward for SureVector. It allows us to offer customers individual vectors or the ability to customize any fragment in the SureVector system.”

“SureVector is an ideal addition to Eurofins Genomics’ gene synthesis and GeneStrands services,” said Uwe Koehler, head of Gene Synthesis and Molecular Biology for Eurofins Genomics. “In this exclusive collaboration, Eurofins Genomics can now offer tailor-made SureVector plasmids, and any component of the SureVector kit can be replaced with customer-specific elements.”
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)